Knights of Columbus Asset Advisors LLC Acquires New Shares in Rhythm Pharmaceuticals, Inc. $RYTM

Knights of Columbus Asset Advisors LLC bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,314 shares of the company’s stock, valued at approximately $1,104,000.

Several other large investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its position in shares of Rhythm Pharmaceuticals by 303.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock worth $28,000 after buying an additional 200 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Rhythm Pharmaceuticals by 97.2% during the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after acquiring an additional 141 shares during the last quarter. Optiver Holding B.V. lifted its holdings in shares of Rhythm Pharmaceuticals by 65.2% in the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock valued at $37,000 after purchasing an additional 144 shares in the last quarter. SBI Securities Co. Ltd. grew its position in shares of Rhythm Pharmaceuticals by 73.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock valued at $37,000 after purchasing an additional 145 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Rhythm Pharmaceuticals by 48.6% in the fourth quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock valued at $39,000 after purchasing an additional 118 shares during the last quarter.

Insider Transactions at Rhythm Pharmaceuticals

In related news, CAO Christopher Paul German sold 5,614 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total transaction of $502,789.84. Following the completion of the transaction, the chief accounting officer owned 160 shares of the company’s stock, valued at approximately $14,329.60. This represents a 97.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on RYTM. Wall Street Zen raised Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Tuesday, April 21st. HC Wainwright dropped their price objective on Rhythm Pharmaceuticals from $110.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Canaccord Genuity Group upped their target price on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Stifel Nicolaus set a $131.00 price target on shares of Rhythm Pharmaceuticals in a report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.81.

Rhythm Pharmaceuticals Trading Up 1.7%

NASDAQ RYTM opened at $92.98 on Friday. The business’s 50-day moving average price is $87.37 and its 200 day moving average price is $97.30. Rhythm Pharmaceuticals, Inc. has a twelve month low of $60.06 and a twelve month high of $122.20. The company has a market capitalization of $6.37 billion, a PE ratio of -29.71 and a beta of 1.94.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.03. The company had revenue of $60.11 million during the quarter, compared to analysts’ expectations of $55.78 million. Rhythm Pharmaceuticals had a negative return on equity of 203.25% and a negative net margin of 93.33%.The firm’s revenue was up 83.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.81) EPS. Equities analysts predict that Rhythm Pharmaceuticals, Inc. will post -3.18 EPS for the current year.

Rhythm Pharmaceuticals Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.